Calendar note: Today is Tuesday, August 4, 2026. The event date provided—2026Q2 earnings call on August 4—is therefore today, not tomorrow.
Waters enters 2Q26 after a very strong first quarter that established two key points: the legacy analytical-instruments franchise is growing well above its historical rate, and the acquired BD Biosciences & Diagnostic Solutions (“BDS”) businesses showed an early improvement in execution. The market now needs evidence that these trends held through a full quarter of ownership, rather than merely a favorable early post-close period.
The central issue is not simply whether WAT beats its guided EPS range. It is whether management can substantiate the earnings algorithm underlying the BDS transaction:
WAT shares closed at $374.78 on August 3, up roughly 24% since May 4 and about 9% since the post-1Q earnings close on May 5—an indication that investors have already credited a meaningful part of the early execution story. The bar is therefore likely centered on the quality of 2H guidance and the credibility of the BDS acceleration, not just a modest quarterly beat.
| Metric | 2Q26 guidance |
|---|---|
| Organic constant-currency revenue growth | 6%–8% |
| Organic reported revenue | $814M–$829M |
| Acquired BDS revenue | ~$802M |
| Total reported revenue | $1.616B–$1.631B |
| Adjusted EPS | $2.95–$3.05 |
| Implied adjusted EPS growth | Flat to +3.4% YoY |
The earnings-growth profile is intentionally muted in 2Q: management has said higher interest expense and the additional share count from the BDS transaction absorb much of the operating benefit, while meaningful cost-synergy savings are expected to begin flowing through the P&L in 3Q26.
The BDS acquisition closed on February 9, 2026, meaning 1Q contained only a partial ownership period. The 2Q report is the first clean test of the combined company’s operating cadence.
In 1Q, BDS revenue was $520M during Waters’ ownership period, or $40M above guidance. On an estimated comparable basis, revenue grew 7% during the stub period; on a full-quarter pro forma basis, acquired-business revenue was flat, or approximately +3% excluding a $20M respiratory-testing headwind.
The early improvement was most visible in:
1. Underlying BDS growth above the reported comparison.
Management guided BDS to approximately $802M of 2Q revenue, described as about 2.5% reported growth. The more important disclosure will be full-quarter comparable growth by division, especially growth excluding the respiratory-testing headwind and China-related pressure.
2. Confirmation that Biosciences is recovering—not merely stabilizing.
The flow-cytometry franchise remains exposed to softer U.S. academic/government demand, China restrictions, and a lack of localized products. Investors should look for commentary on orders and tenders ahead of planned China localization in the second half.
3. Continued Diagnostic Solutions momentum.
Microbiology is the most visible turnaround opportunity. The key markers are demand trends for the BACTEC installed base, initial commercial traction for the BACTEC FXI blood-culture system, reagent-rental compliance actions, and whether respiratory testing has become a less material drag.
4. Evidence that execution initiatives are translating from activity to revenue.
Management cited a large opportunity in legacy reagent-rental contracts and pricing discipline. These actions were not fully embedded in the prior guide, which makes them a potential source of upside—but also means investors will expect tangible evidence rather than broad strategic commentary.
The legacy Analytical Sciences business delivered 12% constant-currency growth in 1Q, driven by:
The quality of that result was particularly strong in consumables and service, which are more recurring than instruments. Still, investors should not extrapolate the 1Q rate mechanically: management indicated that the quarter benefited from additional working days, which added roughly 2 percentage points to total legacy revenue growth.
A clean 6%–8% organic result should be sufficient; a result closer to the high end, accompanied by strong orders or backlog commentary, would reinforce confidence that the legacy business remains durable.
Waters raised its full-year outlook after 1Q to:
| Full-year 2026 guidance | Current outlook |
|---|---|
| Organic constant-currency growth | 6.5%–8.0% |
| Organic reported revenue | $3.370B–$3.420B |
| BDS revenue | ~$3.035B |
| Total reported revenue | $6.405B–$6.455B |
| Adjusted EBIT margin | 28.2% |
| Adjusted EPS | $14.40–$14.60 |
The current framework embeds a relatively cautious second half: roughly 6% organic constant-currency growth in the legacy business and a measured acceleration in BDS. That makes the setup constructive if 2Q execution is solid, but it also means investors will look for one of two outcomes:
A maintained guide paired with softer BDS or China commentary would likely be received less favorably, given the stock’s advance since the 1Q report.
The BDS transaction transformed WAT’s capital structure and GAAP earnings profile.
This makes adjusted EPS the near-term valuation metric investors are likely to emphasize. However, the long-term case depends on converting earnings into cash and de-levering. Watch for:
What was full-quarter pro forma growth in Biosciences and Diagnostic Solutions?
The acquired revenue number alone is insufficient; underlying growth and segment trends matter most.
Did BDS growth accelerate sequentially after excluding respiratory testing and China?
This is the cleanest read on whether the turnaround is genuinely taking hold.
What is the early demand signal for BACTEC FXI?
The product can support both replacement revenue and broader microbiology growth.
Has China localization begun to improve the Biosciences order funnel?
Management previously targeted initial localized manufacturing in 3Q, making 2Q order commentary especially important.
How much 2Q upside, if any, came from pricing, contract compliance, or other actions not embedded in guidance?
Are the anticipated 3Q cost-synergy savings still on schedule?
This is pivotal to the expected second-half margin progression.
Is 2026 adjusted EPS guidance still conservative after 1H execution?
With 1Q well ahead of expectations, the market will focus on whether management preserves prudence or signals upside.
The bullish case: Waters can pair a structurally strong legacy analytical-sciences franchise with an improving diagnostics and biosciences platform. If 2Q confirms that BDS is moving from stabilization to sustainable growth, the company has multiple levers—pricing, contract compliance, China localization, installed-base replacement, service attachment, cross-selling, and cost synergies—to support accelerating earnings beyond 2026.
The risk case: The 1Q BDS outperformance may prove harder to repeat once the business is measured on a full-quarter basis. China, U.S. academic/government demand, respiratory-testing comparisons, integration costs, leverage, and a more complex reporting structure all create execution risk. A weak BDS growth print or lack of confidence in the second-half ramp would challenge the premium embedded in the shares.
What would constitute a good report: organic growth at or above the midpoint of guidance, BDS results that show clear sequential improvement on a comparable basis, confirmation of 3Q synergy realization, and at least a maintained full-year outlook with credible upside framing.
Sources reviewed: Waters 1Q26 earnings release, 1Q26 earnings-call transcript, and 1Q26 Form 10-Q; WAT historical share-price data through August 3, 2026.